Impact of universal hepatitis B vaccination on antenatal hepatitis B prevalence in the Midlands region of the North Island, New Zealand.
N Z Med J
; 124(1332): 40-4, 2011 Apr 15.
Article
em En
| MEDLINE
| ID: mdl-21747422
ABSTRACT
AIM:
Universal hepatitis B vaccination has now been in place in New Zealand for 22 years. A retrospective laboratory data study has been carried out to give objective evidence of the impact that this is having on hepatitis B prevalence in the antenatal population.METHOD:
A retrospective data search was performed of all antenatal hepatitis B surface antigen (HepBsAg) tests carried out at Pathlab Laboratories between 1997 and 2009.RESULTS:
When the change in prevalence with time is examined, there is a clear downwards trend in antenatal hepatitis B prevalence rates from 1997 to 2009. Dividing the antenatal population into different age groups, the downward trend is most marked for those aged =20 years.CONCLUSION:
The prevalence of hepatitis B infection in the antenatal population in the Midlands region of New Zealand is now declining and is likely to be as a result of the introduction of the hepatitis B vaccine onto the universal schedule throughout New Zealand in 1988. This would also explain why the decrease is most marked in antenatal women below the age of 20.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Complicações Infecciosas na Gravidez
/
Vacinação em Massa
/
Vacinas contra Hepatite B
/
Hepatite B
Tipo de estudo:
Diagnostic_studies
/
Incidence_studies
/
Observational_studies
/
Prevalence_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Screening_studies
Limite:
Adult
/
Female
/
Humans
/
Pregnancy
País/Região como assunto:
Oceania
Idioma:
En
Revista:
N Z Med J
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Nova Zelândia